Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02279082 | DFN-02 Open Label Safety Study in Patients With Acute Migraine | PHASE3 | COMPLETED | 167 | — | — | Sep 1, 2014 | Mar 1, 2016 | Mar 9, 2018 | 24 | United States |
| Arm | Type | Description |
|---|---|---|
| DFN-02 | EXPERIMENTAL | DFN-02 to be taken during migraine attack |
| Name | Type | Description |
|---|---|---|
| DFN-02 | DRUG | Active Experimental Drug |
Inclusion Criteria: 1. Patients with a history of acute migraine (using International Classification of Headache Disorders \[ICHD\] criteria, second edition); 2. Patients who, in the opinion of the investigator, are willing and able to: * Return to the study site within 72 hours of the first us...